BRPI0607140A2 - compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism - Google Patents
compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolismInfo
- Publication number
- BRPI0607140A2 BRPI0607140A2 BRPI0607140-6A BRPI0607140A BRPI0607140A2 BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2 BR PI0607140 A BRPI0607140 A BR PI0607140A BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- cells
- stimulating
- carbohydrate
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
COMPOSTO, USO DO COMPOSTO E/OU USO DE UM SAL, LACTONA OU PRó-MEDICAMENTO FARMACEUTICAMENTE ACEITáVEL DO DITO COMPOSTO, COMPOSIçãO FARMACêUTICA, KIT FARMACêUTICO, MéTODO PARA ESTIMULAR A CAPTAçãO DE GLICOSE PELAS CéLULAS MUSCULARES E/OU CéLULAS DE ADIPóCITO, MéTODO PARA ESTIMULAR A SECREçãO DE INSULINA PELAS CéLULAS PANCREáTICAS CéLULAS-13 E MéTODO PARA O TRATAMENTO DE UM MAMìFERO QUE TEM UM DISTúRBIO DO METABOLISMO DE CARBOIDRATOS OU DE LIPìDIOS. A invenção refere-se aos isómeros configuracionais de 4-hidróxi isoleucina e às lactonas, sais farmaceuticamente aceitáveis e pró-medicamentos dos mesmos, aos processos para a sua preparação e às composições farmacêuticas que compreendem os mesmos. Os isómeros da invenção exibem atividade insulinotrópica e, desse modo, podem ser úteis para a prevenção e o tratamento dos distúrbios do metabolismo de carboidratos ou de lipídios, incluindo o diabetes meilitus (diabetes tipo 1 e tipo 2), pré-diabetes e a Síndrome Metabólica.COMPOUND, USE OF COMPOUND AND / OR USE OF A PHARMACEUTICALLY ACCEPTABLE SALT, LACTONA OR PRODUCT OF COMPOUND, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL KIT, METHOD FOR STIMULATING CELLULULAR CELLULLE OR CELLULLE CELLULATION PANCREATIC CELL-13 CELLS AND METHOD FOR THE TREATMENT OF A MAMMIFER THAT HAS A DISORDER OF CARBOHYDRATE OR LIPID METABOLISM. The invention relates to configurational isomers of 4-hydroxy isoleucine and to lactones, pharmaceutically acceptable salts and prodrugs thereof, processes for their preparation and pharmaceutical compositions comprising them. The isomers of the invention exhibit insulinotropic activity and thus may be useful for the prevention and treatment of carbohydrate or lipid metabolism disorders, including diabetes meilitus (type 1 and type 2 diabetes), prediabetes, and the syndrome. Metabolic
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65441305P | 2005-02-18 | 2005-02-18 | |
PCT/IB2006/001758 WO2006117696A2 (en) | 2005-02-18 | 2006-02-17 | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607140A2 true BRPI0607140A2 (en) | 2009-08-11 |
Family
ID=37086084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607140-6A BRPI0607140A2 (en) | 2005-02-18 | 2006-02-17 | compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1853552A2 (en) |
JP (1) | JP2008530198A (en) |
CN (1) | CN101128418A (en) |
AU (1) | AU2006242851A1 (en) |
BR (1) | BRPI0607140A2 (en) |
CA (1) | CA2598491A1 (en) |
MX (1) | MX2007009985A (en) |
WO (1) | WO2006117696A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101252926A (en) * | 2005-03-22 | 2008-08-27 | 因诺迪亚有限公司 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
WO2008154743A1 (en) * | 2007-06-19 | 2008-12-24 | Innodia Inc. | Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof |
WO2009085180A1 (en) * | 2007-12-20 | 2009-07-09 | The Feinstein Institute For Medical Research | Treatment of sepsis and inhibition of mif by d-t4 |
FI3364958T3 (en) * | 2015-10-23 | 2023-04-06 | Navitor Pharm Inc | Modulators of sestrin-gator2 interaction and uses thereof |
WO2018200625A1 (en) | 2017-04-26 | 2018-11-01 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
CN113164414A (en) | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | Polymorphic compounds and uses thereof |
EP4051259A4 (en) | 2019-11-01 | 2023-11-22 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mtorc1 modulator |
CN112089710B (en) * | 2020-08-07 | 2022-04-01 | 郑州大学 | Application of 4-hydroxyisoleucine in preparation of antitumor drugs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2797767B1 (en) * | 1999-08-27 | 2002-06-14 | Centre Nat Rech Scient | USE OF AMINO ACIDS FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF INSULIN RESISTANCES |
MXPA06004698A (en) * | 2003-10-27 | 2006-07-05 | Innodia Inc | Methods and composition for use in treating diabetes. |
EP1657236A1 (en) * | 2004-11-10 | 2006-05-17 | Centre National De La Recherche Scientifique (Cnrs) | Method for preparing diastereoisomers of 4-hydroxy isoleucine |
-
2006
- 2006-02-17 JP JP2007555732A patent/JP2008530198A/en active Pending
- 2006-02-17 CA CA002598491A patent/CA2598491A1/en not_active Abandoned
- 2006-02-17 AU AU2006242851A patent/AU2006242851A1/en not_active Abandoned
- 2006-02-17 MX MX2007009985A patent/MX2007009985A/en not_active Application Discontinuation
- 2006-02-17 WO PCT/IB2006/001758 patent/WO2006117696A2/en active Application Filing
- 2006-02-17 EP EP06765601A patent/EP1853552A2/en not_active Withdrawn
- 2006-02-17 CN CNA2006800050682A patent/CN101128418A/en active Pending
- 2006-02-17 BR BRPI0607140-6A patent/BRPI0607140A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2007009985A (en) | 2008-03-11 |
EP1853552A2 (en) | 2007-11-14 |
CA2598491A1 (en) | 2006-11-09 |
WO2006117696A3 (en) | 2007-01-25 |
CN101128418A (en) | 2008-02-20 |
AU2006242851A1 (en) | 2006-11-09 |
WO2006117696A2 (en) | 2006-11-09 |
JP2008530198A (en) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607156A2 (en) | compound, pharmaceutical composition, use of the compound, pharmaceutical kit, method for stimulating glucose uptake by muscle cells and / or adipocyte cell and method for stimulating pancreatic secretion | |
BRPI0607140A2 (en) | compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism | |
AU2020201457B2 (en) | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | |
KR102396831B1 (en) | Compositions and methods for joint | |
Li et al. | Gastrodin and isorhynchophylline synergistically inhibit MPP+-induced oxidative stress in SH-SY5Y cells by targeting ERK1/2 and GSK-3β pathways: involvement of Nrf2 nuclear translocation | |
ECSP088139A (en) | METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDE | |
UA100384C2 (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
BRPI0516454A (en) | compound, process for preparing a compound, pharmaceutical composition comprising it, its use, method for treating and prophylaxis of diseases, and type II diabetes | |
BRPI0507189A (en) | combined use of a glp-1 agonist and gastrin compounds | |
BRPI0718596B8 (en) | pharmaceutical compositions for combination therapy with sglt-2 and metformin inhibitors | |
BRPI1015120A2 (en) | lipid compound, pharmaceutical and lipid compositions, methods of producing lipid compound and for preventing or treating diseases and uses of at least one compound | |
BRPI0618552B8 (en) | pyrimidine derivative compounds linked to oxygen, pharmaceutical composition that includes said compounds, method of synthesis of the compounds and therapeutic uses thereof | |
WO2008124505A3 (en) | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders | |
NO20054408L (en) | 3 (2-Phenyl-oxazol-4-yl-methoxy) -cyclohexylmethoxyacetic acid derivatives and similar compounds as PPAR modulators for the treatment of type 2 diabetes and arteriosclerosis | |
Chmiel-Perzyńska et al. | Novel aspect of ketone action: β-hydroxybutyrate increases brain synthesis of kynurenic acid in vitro | |
BRPI0611550A2 (en) | use of a compound selected from the group consisting of 4-hydroxy isoleucine isomers, 4-hydroxy isoleucine analogs, and lactones, salts, metabolites, solvates and / or pharmaceutically acceptable prodrugs of said isomers and analogs, compound, pharmaceutical kit , pharmaceutical composition, use of the compound and kit with compound | |
BR112015001056A2 (en) | compound, pharmaceutical composition, methods for the treatment of aldosterone-mediated disorders, for the treatment of disease or a condition, for the treatment of metabolic syndrome, for the treatment of a physiological or pathological disease, and for the treatment of chronic kidney disease, insufficiency renal disease or diabetic nephropathy | |
Xiong et al. | Intermittent fasting alleviates type 1 diabetes-induced cognitive dysfunction by improving the frontal cortical metabolic disorder | |
Ohno et al. | The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets | |
Kulkarni et al. | Antidiabetic potential of Rourea minor (Gaertn.) root in streptozotocin—induced diabetic rats | |
BRPI0602179A (en) | pharmaceutical composition comprising cyclobenzaprine and aceclofenac in combination | |
Yousaf et al. | Hypolipidemic effect of extra virgin olive oil in diabetic rats | |
Adhikari et al. | Comparative evaluation of antidiabetic activity of fresh juice and ethanolic extract of Sunderban mangrove Rhizophora mucronata Lam. leaves in animal model | |
BR112021026561A2 (en) | Use of a pharmaceutical composition in the manufacture of a medicament for the prevention or treatment of liver disease | |
BRPI0509737A (en) | glycosamine and anti-inflammatory mutual glucosamine prodrugs, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |